1. A New Era in Migraine Prevention

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Focusing Migraine Treatment on the Individual

6. Migraine Treatment Strategies

7. Goal of Acute and Preventive Treatment for Migraine

8. Indications for Migraine Preventive Treatment

9. Recommended Migraine Prevention Treatments: Repurposed Therapies

10. Lack of Persistence and Adherence to Conventional Preventive Treatments

11. Good Practice for Migraine Prevention

12. The Migraine Brain: Pain Signals Spread to Multiple Cortical Areas and Alter Their Excitability

13. Activation of Pain Fibers and Symptom Cascade

14. Proposed Mechanism for the Role of CGRP in Prolonged Activation Headache Phase of Migraine

15. Proposed Mechanism for Prevention of the Headache Phase of Migraine by Anti-CGRP mAbs

16. Anti-CGRP mAbs: Summary of Phase 3 Studies

17. Summary of Phase 3 Findings for the Anti-CGRP mAbs

18. Safety of Anti-CGRP mAbs: Similar to Placebo

19. Results in Patients With Previous Treatment Failures: Erenumab and LIBERTY

20. Reduction in MMD: Fremanezumab and FOCUS

21. Time to Inhibition With IV Fremanezumab: Experimental Finding

22. Proof of Concept of the CGRP Pathway

23. EHF Recommendation on Use of mAbs: Expert Opinion

24. EHF Recommendations for Headache Health Care Service Organization

25. Aids to Management of Headache Disorders in Primary Care

26. Several Risk Factors Predict Progression From Episodic to Chronic Headache

27. Setting and Practical Application

28. Use in Special Populations

29. EMA Indications for the Anti-CGRP mAbs

30. Discussion: Can the Course of Migraine Be Changed?

31. Discussion: Integrating Anti-CGRP mAbs Into Clinical Practice

32. Discussion: The Unknowns of CGRP

33. Concluding Remarks

34. Abbreviations